Insilico Medicine is a global, clinical-stage, generative artificial intelligence (AI)-driven biotech responsible for advancing the first generative AI-discovered and designed drug to human clinical trials. Its end-to-end Pharma.AI platform spans biology, chemistry and clinical development to identify targets and disease hypotheses and design drug candidates. Insilico's pipeline consists of 31 programmes for 29 drug targets in cancer, fibrosis, immunity, CNS and ageing-related diseases. Four programmes have reached the clinical stage, including a lead fibrosis drug in phase II trials. In 2022, Insilico raised $400 million, filed 300 patents, published 200 papers in peer-reviewed journals and nominated 9 preclinical candidates.